Transthyretin Amyloidosis (ATTR), Cardiovascular (CV)
European Society of Cardiology (ESC) 2025
Congress Details
August 29 - September 1, 2025
Madrid, Spain
The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.
For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Filters
Therapeutic Areas
Congress Materials
Presentation Type
Location
Related Materials
Transthyretin Amyloidosis (ATTR)
Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis with Cardiomyopathy: Insights From HELIOS-B
Journal of the American College of Cardiology
Transthyretin Amyloidosis (ATTR)
Vutrisiran Treatment and Changes in Cardiac Parameters and Amyloid Burden Assessed by Cardiovascular MRI
Journal of the American Medical Association
Transthyretin Amyloidosis (ATTR)
Comorbidity Burden in Transthyretin Amyloidosis With Cardiomyopathy: Insights From the HELIOS-B Trial
Journal of the American College of Cardiology
